Drugs / Insulin Lispro Premix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01175811 | Feb 2011 → Nov 2012 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Lispro Premix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01175811 ↗ |
| Route | Subcutaneous | “administered subcutaneously for 24 weeks” NCT01175811 ↗ |